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Available online at www.sciencedirect.comThere remains a great need to develop vaccines against many
of the pathogens that infect mucosal tissues or have a mucosal
port of entry. Parenteral vaccination may protect in some
instances, but usually a mucosal vaccination route is
necessary. Mucosal vaccines also have logistic advantages
over injectable vaccines by being easier to administer, having
less risk of transmitting infections and potentially being easier
to manufacture. Still, however, only relatively few vaccines for
human use are available: oral vaccines against cholera,
typhoid, polio, and rotavirus, and a nasal vaccine against
influenza. For polio, typhoid and influenza, in which the
pathogens reach the blood stream, there is also an injectable
vaccine alternative. A problem with available oral live vaccines
is their reduced immunogenicity when used in developing
countries; for instance, the efficacy of rotavirus vaccines
correlates closely with the national per capita income.
Research is needed to define the impact of factors such as
malnutrition, aberrant intestinal microflora, concomitant
infections, and preexisting immunity as well as of host genetic
factors on the immunogenicity of these vaccines.
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Introduction
There remains a great need to develop vaccines against
many of the pathogens that infect or take their departure
from a mucosal tissue (Table 1). In some cases, such as
poliovirus and Salmonella typhi, the pathogens cause dis-
ease only after spreading to non-mucosal tissues, but
more often they exert their pathogenic effects locally
on the mucosal tissue. Collectively, these infections have
a serious negative impact on global health by causing
more than 3 billion disease episodes and 3 million deaths
each year [1]. They also represent a tremendous chal-
lenge for vaccine development. Although parenteral
Open access under CC BY-NC-ND license.www.sciencedirect.com immunization in some cases can protect against mucosal
pathogens, in most cases a mucosal vaccination route is
necessary. In comparison to injectable vaccines, mucosal
vaccines would also in general be easier to administer,
have less risk of transmitting infections and may also
allow simplified manufacturing. Still, however, only a
handful of mucosal vaccines for human use are available
(Table 2) as compared to more than 30 injectable
vaccines.
This review summarizes the properties of currently
licensed mucosal vaccines, and when there also exists
an injectable vaccine for the same infection compares the
mucosal and parenteral alternatives.
Determinants for choice of vaccination route
Mucosal pathogens differ in the way they cause infection
and disease. Depending on the pathogen, a vaccine may
need to be administered topically or may protect also after
parenteral administration. Injectable vaccines of docu-
mented efficacy are available alongside with mucosal
vaccines against polio, typhoid, and influenza (Table 2).
How parenteral vaccines may protect against selected
mucosal infections
The main factors explaining how parenteral vaccination
can protect against some but not most mucosal pathogens
relate to the site of infection, the invasiveness of the
pathogen, and previous natural exposure.
Differential mucosal permeability
Mucosal tissues differ in their permeability for serum-
derived antibodies. The lower respiratory tract and the
female genital tract are relatively permeable, in contrast to
the small intestine that is essentially impermeable to blood
proteins unless it is affected by inflammation. Consistent
with this, injectable pneumococcal vaccines can in addition
to protecting against blood-borne infection, via transuda-
tion of serum anti-capsular antibodies also provide some
protection against lung pneumonia. By contrast, cholera
and enterotoxinogenic Escherichia coli (ETEC) infection
are examples of non-inflammatory small intestine infec-
tions, in which vaccine protection is mediated by locally
produced secretory IgA (SIgA) antibodies and normally
requires oral-mucosal administration.
Invasion and inflammation
Parenteral vaccination may also work against those enteric
pathogens, such as Shigella bacteria, that are translocated
across the epithelium through Peyer’s patch ‘M’ cells to
infect enterocytes from the basolateral side, where they
come in contact with serum-derived antibodies. Likewise,Current Opinion in Immunology 2012, 24:343–353
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Table 1
Examples of important bacterial and viral infections primarily affecting or entering through a mucosal surface
Respiratory tract
Streptococcus pneumonie, Mycoplasma pneumonia, Mycobacterium tuberculosis, influenza virus, respiratory syncytial virus (RSV), rhinoviruses
Gastrointestinal tract
Helicobacter pylori, Vibrio cholerae, Enterotoxigenic Escherichia coli (ETEC), Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC),
Campylobacter jejuni, Salmonella spp., Shigella spp., Clostridium difficile, Cryptosporidium, rotaviruses, calici viruses, polioviruses
Uro-Genital tract
Urinary pathogenic Escherichia coli (UPEC), Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex virus (HSV), human papilloma viruses
(HPV), human immunodeficiency virus (HIV)serum antibodies can effectively attack pathogens that
cause disease after inducing inflammation in the submu-
cosal lymphoid tissues (most Salmonellae spp. and Campy-
lobacter jejuni) or, even better, after entering the blood
stream, as for S. typhi or polio virus.Table 2
Internationally licensed vaccines for human use against mucosal infe
Vaccines against Administration route Type 
Cholera Oral Inactivated V. cholerae bacter
(Ca 1011 heat-killed or formali
and El Tor O1 Inaba and Ogaw
rCTB)
Oral Inactivated V. cholerae bacter
composition as above+ 5  1
O139 bacteria)
Oral Live attenuated V. cholerae O
HgR, 108–109 cfu)
Typhoid Oral Live attenuated S. typhi bacte
Ty21a)
Parenteral Purified Vi polysaccharide 
Rotavirus Oral Live attenuated, mono-valent r
human rotavirus strain, specifi
derived from a human rotaviru
Oral Live attenuated, penta-valent 
reassorted human-bovine stra
G1, G2, G3, G4 and P1 [8])
Influenza Intranasal Live attenuated, trivalent influe
adapted A and B viruses adju
identified seasonal needs, e.g
A[H3N2] and B, ca 107 of eac
Intranasal Similar to above 
Polio Oral Live attenuated, trivalent polio
strain type 1, type 2 and type 3
each per 0.1 ml dose)
Oral Live attenuated, bivalent polio
strain, type 1 and type 2, ca 1
per 0.1 ml dose)
Oral Live attenuated, monovalent p
strain, type 1, at least 106 CC
dose)
Parenteral Inactivated, trivalent poliovirus
inactivated type 1, type 2 and
strain derivatives)
Same grown in GMK cells
Current Opinion in Immunology 2012, 24:343–353 Mucosal immunological priming
Previous exposure to the pathogen, leading to mucosal
priming, is another determinant. Although the old inject-
able whole-cell cholera vaccines never gave rise to
impressive or long-lasting immunity, they could inducections
Trade name Producer
ia + CTB toxoid
n-killed classical
a bacteria + 1 mg
Dukoral1 Crucell-Sweden
ia (Same O1
010 formalin-killed
ORC-Vax1
Shanchol1
VaBiotech (Vietnam)
Shanta Biotechniques (India)
1 bacteria (CVD- Orochol1 or
Mutachol1
Berna/Crucell (Switzerland)
– not produced after 2004
ria (Aro S. typhi Vivotif1 Crucell (Switzerland)
Typhim Vi1
Typhrix1
Sanofi Pasteur (France)
GlaxoSmith Kline (Belgium)
otavirus (RIX4414
city G1P [8]
s isolate)
Rotarix1 GlaxoSmith Kline (Belgium)
rotaviruses (5
ins expressing
RotaTeq1 Merck (USA)
nza viruses (cold-
sted to WHO-
. 2009 A[H1N1],
h)
FluMist1 MedImmune
Nasovac1 Inst Exp Med., Russia
 viruses (Sabin
; ca 106 CCID50 of
Orimune1
OPV
OPV
OPV
Wyeth-Lederle (USA)
Novartis (Italy)
BIBCOL (India)
BioFarma (Indonesia), etc.
viruses (Sabin
06 CCID50 of each
Poliomyelitis
vaccine,Type1 &
Type3
Sanofi Pasteur (France)
olioviruses (Sabin
ID50 per 0.1 ml
Poliomyelitis
vaccine, Type1
Sanofi Pasteur
Novartis
GSK
es (formalin-
 type 3 wild-type
Imovax Polio1
VeroPol
Ipol1
Sanofi-Pasteur-MSD
State Serum Institute (DE)
Sanofi Pasteur, etc.
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elderly population in cholera endemic settings [2].
Likewise, parenteral polio vaccination protects not only
against paralytic disease but may also reduce fecal
transmission in polio endemic settings [3]. These
effects are explained by the ability of these vaccines
to stimulate protective SIgA antibody responses in the
gut of individuals previously primed via natural muco-
sal exposure [4,5].
Choice of mucosal vaccination route for site-directed
immune responses
It was initially thought that immune responses induced at
one mucosal site would be disseminated widely to other
mucosal tissues. However, later work has shown that the
mucosal immune system has a high degree of anatomic
compartmentalization related to the migratory properties
of lymphocytes activated at different mucosal sites
(reviewed in [6]). This imposes distinct constraints on
the choice of mucosal vaccine administration route.
In general, the strongest immune response is obtained at
the site of vaccine application and in anatomically adja-
cent mucosae. Thus, oral vaccination induces immune
responses mainly in the upper parts of the intestines,
nasal immunization in the upper respiratory tract, rectal
immunization in the rectum and lower colon, and vaginal
immunization in the genital tract. However, a few notable
exceptions have been found that may allow for more
practical vaccine administration than would otherwise
be possible: for instance, nasal and sublingual immuniz-
ation can induce immune responses in the genital tract
[6]. There are also examples of anatomically distinct but
evolutionary linked mucosal tissues, the best known of
which is the hormonally influenced gut–mammary gland
link in lactating women ensuring that the breast-feeding
baby gets epidemiologically ‘updated’ breast-milk SIgA
antibodies.
Licensed vaccines against enteric infections
Efficacious vaccines are available against three of the
most important gastrointestinal pathogens: V. cholerae,
S. typhi and rotavirus. Notably, however, vaccines are still
lacking against all other enteric pathogens, including
ETEC and Shigella that are the two most important causes
of bacterial enteric infections in children.
Oral cholera vaccines
Almost half of all diarrheas are caused by enterotoxin-
producing bacteria. Among these, V. cholerae (globally in
>98% being of serogroup O1, biotype El Tor) causes the
most severe disease and epidemic outbreaks with case
fatality rates up to 50%. The 7th cholera pandemic, which
started in the early 1960s, now involves almost the entire
developing world reflecting the spread in three distinct
waves of molecularly distinguishable V. cholerae from the
Bay of Bengal [7].www.sciencedirect.com Immune protection is mediated by locally produced
antitoxic and antibacterial SIgA antibodies in the gut,
directed against the cell-binding subunit of cholera toxin
(CTB), and the cell-wall lipopolysaccharide O antigen,
respectively; these antibodies have a synergistic protec-
tive effect [2]. The old injectable whole-cell cholera
vaccines were abandoned in the 1970s owing to poor
efficacy and acceptability. Instead a new generation of
oral cholera vaccines (OCVs) with much better capacity to
stimulate intestinal SIgA antibody responses have
become available and proved to be safe and effective [2].
The as yet only internationally licensed OCV (Dukoral1)
consists of recombinantly produced CTB and inactivated
V. cholerae O1 whole cells of different serotypes (Inaba and
Ogawa) and biotypes (El Tor and classical). It is given
orally in a bicarbonate buffer in two doses 1–2 weeks apart
(in children below age 5 years three oral doses are recom-
mended). The vaccine is safe and stable and has in large
phase 3 efficacy and phase 4 effectiveness trials in
Bangladesh, Peru and Mozambique (see Table 3) con-
ferred 80–90% vaccine-specific protection in the first year
after vaccination (100% protection for the first 6 months in
children below age 5 years) and 60% protection over three
years of follow-up (assuming similar protection in adult
males as found in women). Through its CTB component,
the vaccine also affords 50–70% cross-protection against
LT-producing ETEC for ca 6 months [8–10].
Recently, a second killed OCV has been licensed [11].
This vaccine (ORC-Vax/Shanchol) has the same V. cho-
lerae O1 whole-cell composition as Dukoral but lacks the
CTB component; instead it additionally contains forma-
lin-killed O139 bacteria. The vaccine is given in two oral
doses two weeks apart without a buffer. A recent phase 3
placebo-controlled trial in Kolkata, India found the
vaccine to be 66% efficacious over 3 years of follow-up,
including good protection for the first 2 years also in 1–5
year old children (Table 3) [12]. Both in the Kolkata trial
using Shanchol and the Mozambique trial using Dukoral,
the high levels of vaccine-specific protection found were
against a new type of apparently more virulent [13] O1 El
Tor strains that through gene acquisition produce classi-
cal biotype cholera toxin.
Much effort has also been made to develop a live-
attenuated OCV. One such vaccine, CVD 103-HgR
(Orochol1/Mutachol1), consisting of a genetically
manipulated classical V. cholerae O1 Inaba strain contain-
ing a deletion in the gene encoding cholera toxin, was
licensed in several countries for use in travelers. This
vaccine, which is administered orally as a single dose in a
buffer, was safe, immunogenic and efficacious against
experimental cholera challenge when tested in North-
American volunteers, yet failed to show protection in a
large phase 3 efficacy trial in Indonesia (Table 3) [14].
Production of this vaccine has been suspended sinceCurrent Opinion in Immunology 2012, 24:343–353
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Table 3
Results of efficacy and effectiveness trials of licensed oral cholera vaccines (modified from [67])
Study location (year; [ref]) Type of trial Study population Follow-up period % Protection (95% lower CI)
All ages <5y >5y
Dukoral: Inactivated V. cholerae O1 bacteria + cholera toxin B subunit
Matlab, Bangladesh
(1985–89 [68])
Efficacy trial*
(3 [or 2] doses)
89 586 children (2y–14y) and
adult women (>15y)
4–6 months
1st year
2nd year
3rd year
Cumulative
over 3 years
85% (56%)
62% (50%)
57% (42%)
17% (15%)
50% (39%)
100%
38%
47%
0%
19%
76%
78%
63%
41%
65%
Peru (1994 [69]) Efficacy trial* (2 doses) 1426 adult males (16–45y,
76% of O blood group)
5 months 86% (37%) 86%
Beira, Mozambique
(2003–2004 [70])
Effectiveness trial
(2 doses)
21818 children (>2y) and adults,
including 30% HIV-infected
1 year 84% (43%)
(ITT**: 78%)
82%
(ITT)
67%
(ITT)
Orochol/Mutachol: Live attenuated V. cholerae O1 (CVD103-HgR) bacteria
North Jakarta, Indonesia
(1993–97 [14])
Efficacy trial*
(One dose)
67 508 children and adults
(2–41 years)
1st year
2nd year
3rd year
4th year
18% (89%)
2% (50%)
19% (28%)
14% (24%)
Shanchol/(Orc-Vax): Inactivated V. cholerae O1 and O139 bacteria
Kolkata, India
(2006–09 [12])
Efficacy trial*
(2 doses)
66 900 children
(>1y) and adults
1st year
2nd year
3rd year
Cumulative
over 3 years
41% (13%)
76% (52%)
65% (43%)
68% (55%)
17%
81%
37%
43%
77%
78%
76%
77%
* Randomized placebo-controlled double-blinded study.
** ITT: Intention-to-treat comprising either one or two-doses recipients; other values are as Per-Protocol.2004. Several other live OCVs are in earlier stages of
development with the most advanced candidates being in
phase 2 clinical testing, for example, the Peru-15 vaccine,
which is a toxin-gene deleted, non-motile O1 El Tor
Inaba strain (reviewed in [11]).
Recent findings show that OCVs in addition to their direct
vaccine-specific protection provide substantial indirect
‘herd’ protection to unvaccinated persons in the com-
munity. This results from reduced transmission of cholera
in vaccinated populations, is proportional to the rate of
vaccination in the community and may approach 80% in
settings with high coverage [15]. Mathematical modeling
studies indicate that already with a vaccination coverage
of 50%, the combined effect of direct and indirect protec-
tion would result in a >90% reduction of cholera over
several years [16].
WHO now recommends the use of OCVs together with
other control strategies in both cholera endemic areas and
in selected epidemic situations [17]. The usefulness of
OCVs in cholera outbreaks is supported by mathematical
modeling studies of recent epidemics. Chao et al. [18]
reported that use of OCVs alongside with other interven-
tions in the 2010 cholera outbreak in Haiti would prob-
ably have further reduced morbidity and mortality.
Likewise, Mukandavire et al. [19] after analyzing the
recent severe cholera epidemic in Zimbabwe found that
mass vaccination against cholera deployed strategically inCurrent Opinion in Immunology 2012, 24:343–353 Zimbabwe and surrounding regions could prevent future
cholera epidemics and eventually eliminate cholera from
the region. A study directly testing the effectiveness of
reactive use of OCV in a recent outbreak of cholera in
Hanoi, Vietnam also found the vaccine intervention
effective, providing 76% reduction of cholera [20].
Typhoid fever vaccines
Infection with S. typhi causes 22 million disease episodes
and 200 000 deaths per year in Asia, Africa, and Latin
America [21]. The organism penetrates the mucosa of
both the small and large intestines, and is taken up and
multiplies in submucosal macrophages. After rupture of
these cells, the bacteria can spread to the blood for further
septic dissemination to liver, spleen and lymph nodes.
School-aged children is the primary target group [22], but
S. typhi infection is also common in younger children
[23,24].
Protective immunity is mediated by mucosal IgA anti-
bodies preventing uptake of the pathogen across the
intestinal barrier, and by serum IgG antibodies prevent-
ing further spread of the organism; in addition, cell-
mediated immunity helps recovery from infection. Con-
sistent with this, two types of safe and effective vaccines
are available, an oral live-attenuated vaccine inducing
mucosal immunity and a parenteral vaccine inducing
protective serum IgG antibodies that can attack bacteriawww.sciencedirect.com
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Table 4
Protective efficacies of different typhoid vaccines in various age groups
Vaccine type Age group
(years)
Number of
vaccine doses
Protective
efficacy
Length of
follow up
References
Ty21a, Live oral, liquid 5–21
6–19
3 74%
77%
78%
3 years
3 years
5 years
Reviewed in [22,25]
Ty21a, Live-oral Enteric-coated capsules 5–21
6–19
3 47%
67%
62%
3 years
3 years
7 years
Reviewed in [22,25]
Vi polysaccharide parenteral 5–15
5–44
&2
1
1
1
55%
72%
61%
3 years
17 months
2 years
[71]
[72]
[28]
Vi-rEPA-conjugate parenteral 2–5 2 89% 46 months [73]after invasion. Protective efficacies of these vaccines are
surprisingly similar, ca 50–70% for several years (Table 4).
The live attenuated oral vaccine, Ty21a/Vivotif1, was
developed already in the 1970s by chemical mutagenesis
of a pathogenic S. typhi strain. The current vaccine, which
is marketed as enteric-coated capsules containing lyophi-
lized Ty21a organisms, is approved for use in adults and
children above 5 years of age, and is given in three doses
every other day [22]. It is well tolerated and has, depend-
ing on formulation, provided between 47% and 78%
protection during 3 years of follow-up and even in one
study [25] for up to 7 years after vaccination (Table 4).
The Ty21a vaccine is temperature sensitive requiring a
strict cold chain. A modified freeze-drying process that
keeps the vaccine stable at 25 8C for up to 12 weeks was
recently described [26]. Further, a liquid formulation is
now also being tested for use in children who are too
young to swallow a capsule; a liquid formulation as was
used in early trials may also be more immunogenic than
the encapsulated form (Table 4).
The second licensed vaccine against typhoid consists of Vi
capsular polysaccharide purified from S. typhi. This vaccine
is given intramuscularly in a single dose, and is approved for
use in adults and children over two years of age. Vi poly-
saccharide vaccine is well tolerated and has when tested in
high-endemic countries afforded 70% protection against
typhoid fever for the first 12–18 months and 55% protection
over a 3-year period (reviewed in [22], Table 4). A locally
produced Chinese Vi vaccine has afforded similar (70%)
protection [27]. The Vi vaccine protects by generating
serum antibodies attacking the bacteria after they have
entered into the circulation; S. typhi bacteria are highly
sensitive to both complement-assisted killing and opsono-
phagocytotic effects via Vi-specific antibodies.
Both types of typhoid vaccines may afford indirect herd
protection when vaccine coverage is adequate. This was
noted in a recent cluster-randomized effectiveness trial ofwww.sciencedirect.com Vi polysaccharide vaccine in Kolkata, India [28]: a 44%
reduction in typhoid among unvaccinated members of the
Vi vaccinated clusters was found that significantly con-
tributed to the 61% overall vaccine protection achieved.
Vi polysaccharide has also been conjugated to recombinant
mutant Pseudomonas aeruginosa exoprotein (Vi-rEPA) for
greater immunogenicity particularly in younger age groups
[29]. When tested in children 2–5 years of age, the con-
jugate vaccine afforded 89% protection during 4 years of
follow-up [22,30]. It also gave rise to presumably protective
levels of serum anti-Vi antibody when administered to
Vietnamese infants in three doses at 2, 4 and 6 months of
age [31]. Recently, an alternative Vi-conjugate vaccine (Vi-
CRM197) based on conjugation of Vi polysaccharide from
Citrobacter to a mutated nontoxic diphtheria toxin carrier
protein has also shown excellent immunogenicity when
tested in adults [32]; studies are in progress to evaluate this
vaccine in small children in South-East Asia.
Rotavirus vaccines
Rotavirus is the most important cause of diarrheal
mortality in children below 2 years of age. It is estimated
that 453 000 children die from rotavirus diarrhea each year
[33] and another two million are hospitalized [34]. Rota-
virus may account for 40% of all hospitalized gastroenter-
itis cases globally [35,36]; disease rates are surprisingly
similar in industrialized and developing countries but
>85% of deaths occur in Africa and Asia [37].
Two oral attenuated rotavirus vaccines, Rotarix1 and
RotaTeq1, have recently been introduced in more than
150 countries. These vaccines were preceded by a quad-
rivalent oral vaccine (RotaShield) based on a Rhesus
monkey rotavirus strain equipped with human rotavirus
genes [38]. However, this vaccine was soon withdrawn
from the market after being implicated to cause intus-
susception (intestinal invagination) [39].
Knowledge of the mechanisms of disease and immunity
in rotavirus infection remains limited. Most of theCurrent Opinion in Immunology 2012, 24:343–353
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through vomiting and diarrhea. The infection primarily
engages mature intestinal enterocytes leading to cell
death. Diarrhea may be caused by malabsorption second-
ary to the destruction of enterocytes, villus ischemia,
intestinal secretion induced by rotavirus enterotoxin
(NSP4 protein), and/or through activation of the enteric
nervous system by infection of enterochromaffin cells by
rotavirus. The latter mechanism may also be the cause of
nausea and vomiting [40].
With regard to protective immunity, studies in humans
and animals have reported correlations between protec-
tion and rotavirus specific IgA antibodies. Cellular immu-
nity also appears to have a role, although the primary role
of CD4 T cells may be as helper cells for promoting
antibody production and that of CD8 T cells mainly to
facilitate the resolution of infection [41].
Most human rotavirus strains belong to one of five ser-
otypes (G1–G4 and G9). The serotype distribution varies
by country and year [36] and reinfections are common
[42]. RotaTeq and similar vaccine candidates are based on
the concept that serotype-specific neutralizing antibody is
the primary determinant of protection; hence they con-
tain multiple rotavirus strains representing the major
serotypes. The other group of vaccines including Rotarix
instead was developed on the assumption that protection
does not depend solely on neutralizing antibody; these
vaccines are therefore composed of single rotavirus strains
[41].
The RotaTeq vaccine contains five human-bovine reassor-
tant rotaviruses, each consisting of the WC3 bovine strain
that through reassortment expresses the outer capsid
proteins G1, G2, G3, and G4 defining the main human
rotavirus serotypes and the attachment protein P1(8).
The vaccine is given as 3 oral doses in a buffer at one-
month intervals, usually starting at 6 weeks of age. Several
Phase III studies have shown that the vaccine provides aTable 5
Protective efficacies (PE) of internationally licensed rotavirus vaccine
Vaccine Test countries PE (%) Year 1 
RotaTeq USA + Finland 98 
Bangladesh 45.7 
Vietnam 72.7 
Kenya 83.4 
Ghana 65.0 
Mali 1 
Nicaragua 58 
Rotarix Europe 96 
Latin America + Finland 84.7 
South Africa 72.2 
Malawi 49.2 
El Salvador 76.0 
Current Opinion in Immunology 2012, 24:343–353 very high degree of protection in USA and other affluent
countries but has been less efficient in poor countries in
the developing world (Table 5).
Rotarix is a live attenuated human rotavirus vaccine
containing the RIX4414 strain of G1P(8) specificity. It
is administered in two oral doses at least one month apart
to children aged 6–24 weeks. More than 30 clinical trials
have been undertaken [43] showing that Rotarix offers
sustained high protection (80–90% during two years)
against severe rotavirus disease irrespective of serotype
in Europe and Latin America but, similar to Rotateq,
much lower protection in studies in Africa (Table 5).
In most studies, protection induced by Rotarix or Rota-
Teq has been assessed against severe rotavirus disease
requiring hospitalization, but in some trials the protective
effect has also been determined against disease of differ-
ent severity clearly showing more pronounced protection
against severe than against milder forms of disease
[35,44]. Both vaccines have shown very good safety with
no suggestion of causing intussusception [35,45]. As men-
tioned, they have afforded excellent protection against
severe rotavirus disease in industrialized and middle
income countries, but have been less effective when
tested in poor populations in the developing world (Table
5). In fact, we find (Figure 1) a strong correlation between
the protective efficacy of rotavirus vaccines and the gross
national domestic product per capita as tested in different
countries. The reasons for this are still unclear but may be
due to a multitude of different factors as further discussed
below. Since many of these factors may relate to intestinal
problems interfering with live oral vaccines [56,63], it has
been suggested that a parenteral vaccine could be useful
to circumvent the intestinal barrier [46].
Influenza vaccines
Influenza causes up to 1 billion infections, 3–5 million
severe cases, and 300 000–500 000 deaths each year [47].
The highest mortality has been associated with epidemicss in different countries
PE (%) Year2 Overall 2-year PE (%) Reference
88 93 [45]
39.3 42.7 [74]
64.6 63.9 [74]
54.0 64 [44]
29.4 55.5 [44]
19.2 17.6 [44]
n.t. [75]
86 90 [76]
79 81 [35]
n.t. [77]
n.t. [77]
n.t. [78]
www.sciencedirect.com
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Significant correlation between protective efficacy (PE) of internationally
licensed rotavirus vaccines (RotaTeq and RotaRix) and the gross
domestic product (GDP) per capita in different study countries as
evaluated by regression analysis (r = 0.76, p < 0.0005).caused by influenza virus A (H3N2), but influenza A and
influenza B virus epidemics are also common. Therefore,
current influenza vaccines are trivalent formulations
designed to protect against these three viruses [48].
Common influenza symptoms such as fever, headaches, and
fatigue result mainly from proinflammatory cytokines and
chemokines produced by influenza-infected cells. In
addition, influenza virus infection causes significant tissue
damage. The viral hemagglutinin (HA) protein determines
which species and where in the respiratory tract an influenza
virus strain can infect. Strains that are easily transmitted
between people have HA proteins that bind to receptors in
the upper part of the respiratory tract. By contrast, the
highly lethal H5N1 strain binds to receptors that are mostly
found in the lungs. This difference may explain why the
H5N1 strain causes severe viral pneumonia in the lungs, but
is not easily transmitted by people coughing [49].
The main protective mechanism of parenteral influenza
vaccination is the induction of serum antibodies, mainly
IgG, which prevent systemic spread of the pathogen and
may also through transudation exert a local protective
effect at the mucosal surfaces of the lower respiratory
tract. The efficacy of injectable influenza vaccines corre-
lates directly to the IgG anti-HA antibody levels after
vaccination. In general, HA antibody titers of 1:40
provide protection (reviewed in [48]).
Recently, a live influenza vaccine (FluMist) delivered by
intranasal spray and comprising cold-adapted, tempera-
ture-sensitive attenuated virus reassortant strains (that are
being adjusted to the antigenic needs for the actualwww.sciencedirect.com influenza season) was licensed in USA and other countries
[50]. This vaccine induces an immune response that more
closely resembles natural immunity than the response
elicited by the injectable vaccines. Locally produced
SIgA antibodies to virus surface HA and neuraminidase
are important for protection of the upper respiratory tract
and corresponding serum IgG antibodies for protection of
the lower respiratory tract and against viremia. Cell-
mediated immunity, mainly against virus matrix and
nucleoprotein antigens, facilitates clearance of virus
and recovery from illness. The nasal vaccine induces
higher local IgA antibodies in nasal washings and local
cell-mediated immunity but lower serum antibody titers
than the injectable vaccines. Despite these differences in
immune responses, the two types of vaccine have similar
efficacy, 70–90% in healthy individuals when there is a
good antigenic match between vaccine and epidemic
virus (reviewed in [51]).
It should also be recalled that live cold-adapted attenuated
influenza vaccine given through a nasal spray has been used
routinely in Russia since more than 50 years. Current
vaccine contains A(H1N1), A(H3N2) and B vaccine strains
being annually renewed in accordance to WHO recom-
mendations. The vaccine has proved to be safe, immuno-
genic and to afford 30–60% protection depending upon the
degree of fit between the epidemic and the vaccine strains
[52]. Protection has correlated with both serum HA inhi-
bition titers and even more pronounced with the levels of
IgA antibodies in nasal swabs and saliva.
Polio vaccines
During the past decades, the incidence of paralytic polio-
myelitis has declined worldwide. However, although
WHO in 1988 resolved to eradicate poliomyelitis still
as many as 26 countries in 2011 reported at least one case
of clinical infection with wild-type poliovirus, in total
1349 cases [53].
The failure to eradicate polio may partly be ascribed to
the fact that the predominantly used oral live poliovirus
vaccines (OPVs) carry the risks of both inducing vaccine-
associated paralytic poliomyelitis and of being the source
of vaccine derived virulent polioviruses. As the global
eradication of polio is hopefully approaching, concerns
have been raised in most developing countries about the
continued use of OPV, and how to financially and logis-
tically make it possible to replace OPV with the safe but
more expensive inactivated injectable polio vaccine
(IPV).
Oral polio vaccine (OPV)
OPV, developed by Sabin in the early 1960s, consists of a
mixture of three live attenuated poliovirus strains repre-
senting the different serotypes 1, 2, and 3. In addition to
its enormous impact in reducing polio in the world, this
vaccine has also served as a useful tool for elucidatingCurrent Opinion in Immunology 2012, 24:343–353
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Like IPV, OPV produces antibodies in the blood that will
protect against myelitis by preventing the spread of polio-
virus to the nervous system. But, superior to IPV, OPV also
produces a local SIgA immune response in the intestinal
and nasal mucosa, the primary sites for poliovirus entry and
multiplication [3]. The intestinal immune response against
OPV can rapidly stop person-to-person transmission of wild
poliovirus, making mass campaigns with OPV a powerful
strategy for the global eradication of polio [54].
Three or more spaced doses of OPV are required to
generate adequate levels of seroconversion. Vaccination
is recommended at birth, followed by 3 doses at least 4
weeks apart; booster immunizations are also recom-
mended at different intervals. A need for more immuno-
genic OPVs has been identified, and recent work has
supported the use of monovalent OPVs in supplemental
immunization activities [55]. The considerably lower
seroconversion rates against OPV observed in HIV
infected as compared to non-infected African children
[56] may pose an obstacle to global polio eradication and
indicates the need for improved polio vaccines or vacci-
nation strategies. Still, OPV remains the preferred polio
vaccine in most of the world because of its ease of use,
that is, oral administration of a few drops on the tongue,
low cost and potential to quickly halt transmission [54].
Injectable polio vaccine (IPV)
The first licensed polio vaccine, IPV, developed by Salk in
the early 1950s, has until recently been used for polio
eradication in comparatively few countries. However,
because of the OPV-related risk of causing vaccine-associ-
ated paralytic poliomyelitis and vaccine-derived virulent
polioviruses, it has been proposed that cessation of OPV
should be compulsory and be replaced by IPV in order to
achieve complete eradication of polio [57]. IPV has been
shown to prevent poliovirus outbreaks in many different
settings. There is also some evidence of IPV-induced herd
protection achieved by reducing the risk of contact with
infected individuals [58], which may increase chances of
polio eradication even if vaccine coverage is not 100%.
There have been concerns regarding the risk of wild type
polio virus escaping from vaccine production when pro-
ducing IPV. To minimize this problem production of IPV
from the attenuated polio virus strains in OPV has been
attempted with good results [59]. Further, to reduce costs
it was found that IPV could be given intradermally using a
5-fold lower dose than the regular subcutaneous dosage
without any loss of immunogenicity [60].
A need to avoid or overcome ‘tropical barriers’
to mucosal vaccines
Many oral vaccines, primarily live ones, have
shown reduced immunogenicity when used in devel-
oping compared to industrialized countries. ReducedCurrent Opinion in Immunology 2012, 24:343–353 immunogenicity of OPV in developing countries is
identified as a significant obstacle for polio eradication
[3], and, as discussed above, the oral live rotavirus
vaccines have had substantially reduced efficacy when
tested in poor developing countries, which may limit
their impact for the control of rotavirus infections in
such settings. Likewise, the licensed oral live cholera
vaccine (Orochol) and live oral cholera vaccines in
earlier stages of clinical testing have been found to
perform less well in developing country settings [14].
The reasons for the reduced immunogenicity of oral live
vaccines in developing country settings are not completely
understood. It is often attributed to chronic environmental
enteropathy (CEE), also called tropical enteropathy, clini-
cally characterized by malabsorption and histologically by
intestinal inflammation and blunting of small intestinal
villi [61]. Factors that may contribute to CEE include poor
sanitation and intestinal flora overgrowth, and metage-
nomic studies are underway to evaluate the role of the
host microbiome for the development of CEE and for
immune responsiveness to oral vaccines [62]. In addition,
nutrition-related factors, including both protein-calorie
and micronutrient malnutrition, may negatively impact
on mucosal vaccine immunogenicity as may also be the
case with interference from maternal antibodies during
breastfeeding, intestinal parasitic infections, intestinal
mucosal damage and possibly maternal malnutrition
during pregnancy [63]. Host genetic factors may also
contribute to the observed differences in responsiveness
to mucosal (and other) vaccines in different populations.
Vaccines designed for oral administration will need to be
adjusted to these potential problems in order to maximize
benefits for all children. Oral vaccines, when given to
children in developing countries, may require specific
measures to realize their full benefit such as higher doses
of vaccine; additional booster doses; nutritional supple-
ments; withdrawal of breast milk before vaccine admin-
istration; and deworming medications. A few such
strategies have been tried with promising results, in-
cluding co-administration of vaccines with zinc and vita-
min A [64], withdrawal of breast milk for a few hours
before oral vaccination [65], and treatment of helminths
before vaccination [66].
Conclusions and perspectives
For many years, mucosal immunity and mucosal vaccines
have attracted less than their due share of research and
development. A much improved knowledge about the
mucosal immune system in recent years together with
methodological improvements for measuring local immune
responses, both antibodies and cell-mediated immunity,
has led to a rapidly increased interest for mucosal vaccine
development. Several new mucosal vaccines are in differ-
ent stages of clinical testing, including both attempted
improved alternatives to existing vaccines and vaccineswww.sciencedirect.com
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ETEC diarrhea, shigellosis, and calicivirus infections.
However, the development of a broader range of mucosal
vaccines, especially subunit vaccines based on purified
antigens, will require access to improved antigen delivery
systems as well as effective adjuvants. Significant
advances have recently been made in both of these fields
leading to products that are now in clinical testing [6].
Still, their usefulness in genetically diverse human sub-
jects who also may differ significantly in their intestinal
flora, nutritional status and previous immunological
experience, all of which are factors that have been found
to affect mucosal vaccine efficacy, remains to be defined.
As discussed above, several mucosal vaccines have been
found to work less well in developing country settings
than in industrialized countries. It is a major challenge to
better understand the basis for and find practical means to
avoid or overcome this barrier. Further, the pandemic
HIV infection problem presents additional challenges
with regard to vaccine safety and efficacy, although in
this regard at least the killed mucosal vaccines may have
advantages over injectable vaccines.
Although mucosal vaccine administration in general is
safer than parenteral vaccination, it is notable that two
recently developed mucosal vaccines for human use, a
first-generation live attenuated oral rotavirus vaccine
(RotaShield) and a nasal influenza subunit vaccine given
together with (unmodified) E. coli LT as adjuvant were
withdrawn after a short period on the market because of
adverse reactions. This underlines the difficult and chal-
lenging task for all vaccines to combine vaccine and
adjuvant efficacy with safety and public acceptability.
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